Nurix Therapeutics, Inc. (NRIX) Q3 2024 Earnings
NRIX·Reported October 11, 2024·Before market open
Nurix Therapeutics, Inc. reported Q3 2024 revenue of $12.6M, missed analyst consensus of $12.8M by $222.0K. Diluted EPS came in at $-0.67.
Revenue
$12.6Mmissed by $222.0K
Consensus: $12.8MDiluted EPS
$-0.67met estimate
Consensus: $-0.67
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Nurix Therapeutics, Inc.'s Q3 2024 earnings report.
Nurix Therapeutics, Inc. (NRIX) reported Q3 2024 earnings on October 11, 2024 before market open.
Nurix Therapeutics, Inc. reported revenue of $12.6M and diluted EPS of $-0.67 for Q3 2024.
Revenue missed the consensus estimate of $12.8M by $222.0K. EPS beat the consensus estimate of $-0.67 by $0.00.
You can read the 10-Q periodic report (0001549595-24-000131) directly on SEC EDGAR. The filing index links above go to sec.gov.